Skip to content
MARKETS / BALCAO / ADTX
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Aditxt, Inc. ADTX

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$3,195
▼ 97.6% YoY
$-43.1M
$-25.7M
Growth
USD 3,195.00
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -43.1
-20M-40M2019202020212022202320242025
Compound annual growth
−84.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−1339188 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -612542.2% · Net -1339187.6%
-500000%-1000000%2019202020212022202320242025
ROE
FY2025 · ROE -1183.4%
-500%-1000%2019202020212022202320242025
Gross margin8.4%
Operating margin-612542.2%
Net margin-1339187.6%
Return on assets-175.9%
EBITDAUSD -19.3M

Each USD of equity lost 1183 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -25.7
-10M-20M2019202020212022202320242025

Total assetsUSD 16.5M
EquityUSD 5.6M
CashUSD 3.2M
Current ratio0.31×

Equity funds 34% of total assets.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.0··
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B·······
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0·−0.0−0.0···
EPS, diluted $−1153.83−22147415.22−27038.26−595.60−121.18−1.33−1.52
Dividend / sh $·······
Payout %·······
ROE %−1183.4−455.2−307.6−359.4−437.6−224.3·
Shares out B0.000.000.000.000.000.010.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 34 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 61 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018

Share this section

Download image